Every 10-Q that Beta Bionics, Inc. (BBNX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BBNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBNX filings page.
Beta Bionics, Inc. reported strong top-line growth but continued losses for the quarter ended June 30, 2026. Net sales for the quarter were $32.0 million, up from $23.2 million a year earlier, driven by the iLet insulin delivery device and its single-use consumables. Six‑month net sales reached $59.6 million. Gross profit for the first half was $35.3 million, but higher research and development, sales and marketing, and general and administrative expenses of $85.2 million led to a six‑month net loss of $45.3 million, similar to the prior‑year period.
As of June 30, 2026, the company held $44.3 million in cash and cash equivalents and $180.8 million in short‑ and long‑term U.S. Treasury investments, with total assets of $292.4 million and stockholders’ equity of $256.4 million. Net cash used in operating activities for the first half was $38.5 million. Revenue is increasingly shifting toward the pharmacy benefit plan channel, which generated $22.3 million of six‑month sales versus $37.3 million from the durable medical equipment channel. The company continues to invest in next‑generation products, including the Mint tubeless patch pump and a bihormonal iLet system, and has begun enrolling adults with type 2 diabetes in a pivotal U.S. trial. In January 2026, the FDA issued a Warning Letter citing quality system and reporting deficiencies at the Irvine, California facility following a June 2025 inspection.
Beta Bionics, Inc. reported strong revenue growth but continued losses for the quarter ended March 31, 2026. Net sales rose to $27.6 million from $17.6 million a year earlier, driven by expanding adoption of the iLet insulin delivery system and recurring single-use products across both durable medical equipment and pharmacy benefit channels.
Gross profit nearly doubled to $16.4 million, but rising investments in research and development, sales and marketing, and general and administrative functions pushed operating expenses to $40.7 million, resulting in a net loss of $21.9 million, an improvement from $28.7 million in the prior-year period. The company ended the quarter with $30.3 million in cash, cash equivalents and restricted cash and $209.2 million in short- and long-term investments, supporting ongoing commercialization and pipeline development, including a patch pump and a bihormonal iLet system.
Beta Bionics (BBNX) reported Q3 results showing rapid top-line growth as it scales commercialization of the iLet Bionic Pancreas. Net sales were $27.3 million for the quarter, up from $16.7 million a year ago, driven by both device and recurring single‑use products across durable medical equipment and pharmacy channels. Gross profit reached $15.1 million, reflecting higher volumes.
Operating expenses rose with commercialization: research and development $8.2 million, sales and marketing $16.0 million, and general and administrative $7.9 million. The company posted a net loss of $14.2 million in Q3 and $59.7 million for the nine months. Loss per share was $0.33 on 43.6 million weighted‑average shares.
Liquidity strengthened post‑IPO. As of September 30, 2025, cash and cash equivalents were $38.5 million, short‑term investments $190.2 million, and long‑term investments $45.3 million. Total assets were $330.0 million and stockholders’ equity was $294.8 million. In January 2025, the company completed an IPO with approximately $190.4 million in net proceeds and a $15.6 million concurrent private placement; preferred stock and certain warrants converted to common. Shares outstanding were 44,024,631 as of October 24, 2025.